This is the story of Joseph, a 28-year-old man who's made a very difficult choice. On December 2024, Joseph Awuah-Darko shared the difficult decision of choosing euthanasia on Instagram. He's not physically sick, but he's been battling a severe mental illness called bipolar disorder for many years. He's tried many treatments, but nothing has helped him feel better. He feels like the pain of his illness is too much to bear. He's shared his story publicly to help people understand what he's going through and to show how serious mental illness can be. Joseph shared a post that explained why he is making this decision, in the caption of the post he shared, “I am not saying that life (as a phenomenon) isn’t worth living. It ABSOLUTELY is. What I am saying is that the mental weight of MINE has become entirely unbearable.”

Joseph has bipolar disorder, which means his moods swing very high and very low. He's had this illness for a long time, and it makes his life very difficult. On his Instagram, he has shared his journey with bipolar, he explained that he tried many different medicines and therapies, but they haven't worked. He feels constant pain and suffering because of his illness. He's reached a point where he feels like he can't go on anymore. He's been open about his struggles on social media, hoping to raise awareness about mental health. He wants people to understand how much he suffers and why he's made this decision.

Euthanasia in the Netherlands

Government of the Netherlands explain that in the Netherlands, it's legal for a doctor to help someone end their life if they meet certain conditions. This is called euthanasia. Joseph has applied for this because he feels his mental illness is causing him unbearable suffering. There are rules and procedures that doctors must follow. They have to make sure the person understands their decision and that there are no other options. The process can take a long time, sometimes years. Joseph believes that having the option of a peaceful and dignified death is important. He wants to have control over how his life ends.

The Last Supper Project

When Joseph shared his decision, people had many different reactions. Some people understood and supported him. Others were sad and hoped he would change his mind. He even received some negative comments. But he also received many kind messages, including invitations to have dinner. This inspired him to start "The Last Supper Project," where he travels and shares meals with strangers. In the caption he explained, “‘The Last Supper Project’ is based on the Harvard Study of Adult Development which speaks to the importance of quality relationships and community as the greatest predictor for happiness. And I feel connecting this way around food as a great unifying vessel could be beautiful.”

The Last Supper Project is one of the longest studies, lasting for more than 80 years, done on adult development. In an Author Speaks edition of McKinsey & Company, the study’s director Robert Waldinger explained the study wanted to know what helps people have happy and healthy lives, even if they had problems when they were young. Most studies only looked at what goes wrong, but this one wanted to know what goes right. The study emphasizes that it is never too late for positive changes. People often believe they are too old or incapable of forming good relationships. They may think happiness is out of reach. However, the study has observed individuals who found happiness unexpectedly.

Joseph wants to connect with people and enjoy these moments while he waits for his euthanasia request to be approved. He sees these dinners as a way to find joy and connection in his final chapter. He still has bad days, but he finds comfort in these shared experiences.

Hepatitis remains one of the most misunderstood liver conditions, largely because it isn't a single disease but a group of infections—A, B, C, D, and E—each of which behaves very differently once it enters the body.

The question "can hepatitis be cured?" doesn't have one straightforward answer. The truth lies somewhere between full recovery and lifelong management, depending entirely on which type of hepatitis a person has contracted.

Not All Hepatitis Is the Same

Hepatitis A and E are generally short-lived infections. The liver, in most cases, clears these viruses naturally without any specific antiviral medication. Rest, hydration, a balanced diet, and avoiding alcohol are usually enough to help the body recover fully. Chronic infection is rare with these two types, and when it does occur, particularly with Hepatitis E in people with weakened immunity, it can still be treated successfully.

Hepatitis C tells a much more encouraging story. Thanks to advances in medicine, Direct-Acting Antivirals, or DAAs, now cure more than 95 percent of cases. These are oral tablets taken for roughly eight to twelve weeks, and they carry minimal side effects compared to older treatments. For patients diagnosed early, Hepatitis C is, quite genuinely, curable.

Where Treatment Manages Rather Than Cures

Hepatitis B and D are a different story altogether. When the infection is acute, the body often fights it off on its own without much trouble.

Chronic cases, though, are far tougher to deal with. As of now, no medication can fully remove the Hepatitis B virus from the body once it settles in. What doctors can do is keep it under control, usually through antiviral tablets or interferon injections, so that it doesn't quietly damage the liver over time and lead to cirrhosis or cancer. For many patients, this isn't a short course of treatment. It's something they may need to stay on for years, and in several cases, for the rest of their lives.

Hepatitis D is considered the more severe of the two, and it only shows up in people who already have Hepatitis B; it cannot infect someone on its own. Treatment choices here are still quite limited. A few newer drugs have shown some promise in keeping the disease in check, but nothing yet counts as an actual cure. When the liver damage has progressed too far, a transplant sometimes becomes the only way forward.

Why Early Diagnosis Changes The Outcome

The single most important factor in determining outcomes across all types of hepatitis is timing. Detected early, Hepatitis C can be eliminated. Detected early, Hepatitis B can be controlled well enough that liver damage never progresses. Left unchecked, however, both can silently damage liver tissue for years before symptoms even appear.

Regular liver function tests, hepatitis screening for those at risk, and vaccination—especially for Hepatitis B—remain the strongest tools available for prevention and timely intervention.

The Bottom Line

Hepatitis doesn't follow a single script, and that's something patients often find confusing at first. Some forms clear up completely with the right treatment, others require ongoing management to keep the virus in check, and in many cases, vaccination and timely screening make the real difference in avoiding complications down the line.

Knowing exactly which type of hepatitis one is dealing with is what allows a doctor and patient to set realistic expectations and work out a treatment plan that actually fits the situation.

The rise of GLP-1 medications such as Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound (tirzepatide) has transformed obesity and diabetes treatment.

However, soaring demand and earlier drug shortages also fueled the rapid growth of compounded GLP-1 drugs, which are now under increasing scrutiny from regulators and medical experts.

Over the past few months, the U.S. Food and Drug Administration (FDA) has intensified its crackdown on compounded GLP-1 products, warning that patients could face quality, dosing, and safety concerns if they obtain these medications from unlawful sources.

What Are Compounded GLP-1 Drugs?

A compounded drug is a medication that is custom-made by a licensed compounding pharmacy to meet an individual patient's specific medical needs. For example, removing an allergen, changing the dosage, or preparing a formulation that is not commercially available.

The FDA said, "Compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed."

Also read: People Are Microdosing GLP-1 Weight Loss Drugs; What Do Experts Have To Say About It?

Why Have Compounded GLP-1 Drugs Become Popular?

Demand for GLP-1 medications for weight loss skyrocketed worldwide between 2022 and 2025, leading to shortages of semaglutide and tirzepatide.

During these shortages, compounding pharmacies were legally allowed under specific circumstances to prepare several versions of these medications.

Many patients turned to compounded GLP-1s because they were often affordable, available, and easier to buy online.

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

FDA Is Tightening Scrutiny

FDA's efforts to restrict this practice include widespread compounding of semaglutide, tirzepatide, and liraglutide.

The agency has proposed excluding these drugs from the list of bulk substances used for large-scale compounding because FDA-approved alternatives are now available.

It has also issued warning letters to companies producing compounded GLP-1 products outside permitted circumstances.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

Recent Research Raises New Concerns

A new University of Colorado Anschutz Medical Campus secret shopper study published in July 2026 found that the compounded GLP-1 market remains active even after shortages have been curbed.

Researchers reported that many online pharmacies were still selling compounded semaglutide or tirzepatide, with some products originating from pharmacies lacking compounding licenses.

Potential Risks of Compounded GLP-1 Drugs

Inaccurate Dosing

Small differences in concentration may result in patients receiving too much or too little medication.

Sterility Concerns

Injectable medicines must be manufactured under strict sterile conditions. Improper preparation increases the risk of contamination.

Different Ingredients

Some compounded products have reportedly used semaglutide salts or added vitamins and other substances that are not present in FDA-approved versions. The FDA has previously stated that certain semaglutide salt forms have not been demonstrated to be safe or effective.

Limited Safety Data

Because compounded products are not FDA-approved, they have not undergone the rigorous clinical trials evaluating effectiveness, manufacturing consistency, and long-term safety.

Counterfeit or Unregulated Products

Experts warn that some websites advertise compounded GLP-1 medications that may not come from legitimate pharmacies at all.

As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to help manage metabolic disorders and obesity, a new trend is rapidly gaining traction on social media - GLP-1 microdosing.

Instead of taking the prescribed doses approved for diabetes or obesity, some users are deliberately taking much smaller amounts, claiming they can lose weight, reduce food noise, avoid side effects, save money, or even improve longevity.

However, experts warn that there is currently little scientific evidence that GLP-1 microdosing is safe or even effective.

What Is GLP-1 Microdosing?

Some people reduce their dose by extending the time between injections, counting "clicks" on injection pens instead of using prescribed doses, or taking customized low-dose formulations.

HealthandMe spoke to Dr. Shehla Shaikh, Consultant Endocrinologist, Saifee Hospital, Mumbai, about the trend of GLP-1 microdosing.

Dr. Shaikh says, "The lowest dose that is supported by evidence for semaglutide is 0 25 mg. While, for tirzepatide, it is 2 5 mg Some people are using much smaller amounts for example using nine clicks on a semaglutide pen which gives about 0 06 mg. Now there are no randomized studies or clear guidelines that show if this kind of micro-dosing is safe or works."

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

Medical experts caution that these practices fall outside approved prescribing guidelines and have not been rigorously studied.

The expert says, "One big worry is how accurate the dose is. These injectable pens are made to give set approved amounts; not amounts based on people counting clicks. Even a small mistake in counting can mean taking too little medicine which may not work well or too much, which could cause more problems. Since these instructions are complicated, they need careful handling good eyesight and understanding of the device."

Why Are People Trying It?

Fewer Side Effects

Lower Cost

These medications are expensive in various countries. So, people stretch a single prescription by taking less medication than prescribed.

Weight Maintenance

Rather than pursuing significant weight loss, some users say they simply want to maintain previous results or reduce constant food cravings without taking full doses.

Longevity Claims

Online influencers have begun promoting low-dose GLP-1s as potential "longevity drugs." While GLP-1 medications show promise for heart and metabolic health, experts stress that these benefits have only been demonstrated using clinically tested doses, not microdoses.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

The Risks of Microdosing

Reduced Effectiveness

Taking too little medication may fail to adequately suppress appetite, improve blood sugar levels, or achieve meaningful weight loss.

Dr. Shaikh says, "People often choose microdosing because they want to avoid problems reduce appetite with a smaller dose or make a costly medicine last longer. While smaller amounts might help a bit, current information shows that the best and steadiest results come from following the approved ways to take the medicine. Using doses that are too low might not give the results to people who want to lose weight or manage their metabolic health."

Delayed Medical Treatment Or Risk Of Expiration

Experts also say that people with obesity or diabetes could unknowingly receive suboptimal treatment while believing they are protected. Another problem is how long the medicine lasts after it is opened.

Dr. Shaikh explains, "An opened semaglutide pen should be used within 60 days while an opened tirzepatide pen should be used within 30 days. Because microdosing uses the medicine over a longer time, people might keep using it past the time it is safe which could change how good it is."

Inaccurate Dosing

Also read: Could GLP-1 Weight Loss Drugs Help People Take Fewer Sick Days? New Study Says So

Some users manually estimate doses by counting injection pen clicks. Experts warn these devices are designed to deliver specific calibrated doses, making partial dosing unreliable.

The expert says, "Some people think micro-dosing gives similar benefits with fewer problems or lower costs, but this practice has no scientific support and might have several dangers."